157169-61-4

Upstream product

• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 624-28-2 2,5-dibromopyridine 
• 784149-29-7 5-bromo-2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 919361-22-1 (S)-4-Benzyl-3-((S)-2-{6-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-3-ylmethyl}-tetrahydro-furan-2-carbonyl)-oxazolidin-2-one 
• 919361-20-9 (S)-N-((R)-2-Hydroxy-1-phenyl-ethyl)-2-methoxy-2-methyl-3-{6-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-3-yl}-propionamide 
• 1058702-89-8 1-{6-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-3-ylmethyl}-cyclohexanecarboxylic acid ethyl ester 
• 908150-29-8 2-{6-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-3-ylmethyl}-tetrahydro-pyran-2-carboxylic acid ethyl ester 
• 784149-47-9 ethyl 2-({6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl}methyl)tetrahydrofuran-2-carboxylate 
• 784149-46-8 ethyl 1-({6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl}methyl)cyclobutanecarboxylate 

Relevant academic research and scientific papers

Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

A series of novel pyridine-3-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARα/γ agonists with varied isoform selectivity. Based on the results of efficacy studies in

Alpha substituted carboxylic acids

Alpha substituted carboxylic acids of formula (I):

ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS

Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R9a, R10, R", R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

Oxazolidinedione derivatives and their use

Novel 2,4-oxazolidinedione compounds of the formula: STR1 wherein R is a hydrocarbon residue or a heterocyclic group each of which may be substituted; Y is --CO--, --CH(OH)-- or --NR3 -- (wherein R3 is an alkyl group which may be substituted); m is 0 or 1; n is 0, 1 or 2; X is CH or N; A is bivalent straight or branched hydrocarbon chain residue having 1 to 7 carbon atoms; R1 and R2 each are hydrogen or an alkyl group, or R1 and R2 are combined with each other to form a 5- to 6-membered heterocyclic group optionally containing nitrogen; L and M each are hydrogen, or L and M are combined with each other to form a bond, or pharmaceutically acceptable salts thereof, having excellent hypoglycemic and hypolipidemic activities and are useful as anti-diabetics or hypolipidemic agents.

Thiazolidinedione derivatives, their production and use

The object of the present invention is to provide a new thiazolidinedione derivative exhibiting excellent hypoglycemic and hypolipidemic action. Thiazolidinedione derivative represented by the general formula: STR1 wherein n represents an integer from 1 t